Cochlear posts 16% jump in profit for FY11
09 August, 2011 by Tim DeanProving that market jitters don’t necessarily reflect underlying profitability, Cochlear has posted a 10% increase in revenue and 16% jump in profit for FY11.
Market watch: Biotechs take battering as markets lurch
08 August, 2011 by Tim DeanBiotechnology stocks haven’t been spared the tumult of the market with several falls of over 5% today.
Bionomics to extend trials of ovarian cancer treatment
04 August, 2011 by Staff WritersTrials of BNC105 in combination with existing chemotherapy drugs to treat ovarian cancer.
Vaxxas gets $15m injection to develop needle-free vaccine
02 August, 2011 by Tim DeanBiotech start-up Vaxxas has received a $15m venture capital kick start to commercialise needle-free vaccine delivery system Nanopatch.
Plasvacc pulls out of sale to Bioniche
02 August, 2011 by Tim DeanThe proposed acquisition of Plasvacc by Bioniche has been kyboshed, with Plasvacc walking away from the deal after negotiations "collapsed".
Feature: Biosecurity and animal-borne viruses
27 July, 2011 by Fiona WylieCSIRO’s Dr Lin-Fa Wang works in the depths of a national biosecurity facility jam-packed with some of the planet’s nastier viruses that call bats home.
Feature: Battling Hendra virus
27 July, 2011 by Fiona WylieOver the last 15 years, Dr Lin-Fa Wang ‘s group has quadrupled in size and now works on many different aspects of bat biology.
New hope for treatment of Ross River fever
25 July, 2011 by Tim DeanA discovery by scientists at Griffith University’s Institute for Glycomics opens the possibility of a new treatment for viruses that cause inflammation, such as Ross River virus and Dengue Fever.
Ian Frazer partners with US university on DNA vaccine
20 July, 2011 by Tim DeanCoridon and Ohio State University have begun collaborating on testing Coridon’s DNA vaccine for Epstein Barr Virus for the prevention of lymphoproliferative disease.
Feature: Platypus venom spurs drug discovery
19 July, 2011 by Graeme O'NeillThe humble platypus packs a venom containing a veritable witche's brew of peptide toxins, some of which might give insights into new drugs.
QRxPharma files for NDA on MoxDuo
18 July, 2011 by Tim DeanNew Drug Application filed with the U.S. FDA for pain treatment, MoxDuo IR, in the wake of positive phase III results.
CSIRO GM crop attacked by Greenpeace had "negligible" risk
14 July, 2011 by Tim DeanThe Office of the Gene Technology Regulator rated the GM crop destroyed today by Greenpeace activists as posing a "negligible" risk to either people or the environment.
Bioniche to acquire Plasvaac Holdings
05 July, 2011 by Staff WritersBioniche, is set to acquire Plasvaac in order to strengthen its animal health portfolio with Plasvaac’s serum-derived plasma products.
IXC Australia closes doors
04 July, 2011 by Tim DeanIndustry collaboration organisation IXC Australia has ceased trading, citing the loss of a major contract and soft economic conditions.
UniQuest brokers international biofuel partnership
01 July, 2011 by Tim DeanThe University of Queensland and Clemson University in the US will collaborate on research and development on a range of biofuel technologies.
